dynastat
pfizer europe ma eeig - parecoxibnatrium - smerte, postoperative - coxibs, antiinflammatory and antirheumatic products - til kortvarig behandling af postoperativ smerte hos voksne.
xarelto
bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiske midler - xarelto, co-gives sammen med acetylsalicylsyre (asa) alene eller sammen med asa plus clopidogrel eller ticlopidin, der er indiceret til forebyggelse af atherothrombotic hændelser hos voksne patienter efter en akut koronar syndrom (acs) med forhøjet kardiale biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
celebra 100 mg kapsler, hårde
upjohn eesv - celecoxib - kapsler, hårde - 100 mg
celecoxib "krka" 100 mg kapsler, hårde
krka sverige ab - celecoxib - kapsler, hårde - 100 mg
celecoxib "pfizer" 100 mg kapsler, hårde
pfizer aps - celecoxib - kapsler, hårde - 100 mg
clarithromycin "accord" 250 mg filmovertrukne tabletter
accord healthcare b.v. - clarithromycin - filmovertrukne tabletter - 250 mg
seractiv 300 mg filmovertrukne tabletter
nordic drugs ab - dexibuprofen - filmovertrukne tabletter - 300 mg
celecoxib "medical valley" 100 mg kapsler, hårde
medical valley invest ab - celecoxib - kapsler, hårde - 100 mg
dronedaron "aristo" 400 mg filmovertrukne tabletter
aristo pharma gmbh - dronedaronhydrochlorid - filmovertrukne tabletter - 400 mg
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiske midler - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.